# Special Issue

# Innovative and Future Trends in Personalized Medicine for Retinal Diseases

# Message from the Guest Editor

Personalized medicine is rapidly transforming the landscape of retinal disease management, offering the potential for tailored treatments based on an individual's unique genetic and molecular profile. By integrating genomic, epigenomic, and proteomic data, clinicians can gain a deeper understanding of disease mechanisms and tailor therapeutic strategies to an individual's specific needs. The scope of personalized medicine extends beyond therapeutic interventions to encompass preventative strategies, identifying individuals at risk, and implementing preemptive measures to mitigate disease onset or progression. Recent advancements in areas such as imaging technologies, DNA sequencing, gene therapy, and stem cell biology have propelled clinical trials and rapidly changed the therapeutic outlook for retinal diseases. We invite authors to contribute manuscripts that focus on notable advancements in the combined use of cutting-edge diagnostic techniques and targeted treatment strategies for retinal disorders. We aim to enhance our understanding of the complexities associated with personalized medicine in this challenging field.

## **Guest Editor**

Dr. Joanna Dolar-Szczasny

Department of General and Pediatric Ophthalmology, Medical University of Lublin, 20-093 Lublin, Poland

## Deadline for manuscript submissions

31 December 2025



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/234530

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

# Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

#### Editor-in-Chief

#### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

